Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment
Orocidin A/S, a subsidiary of Nordicus Partners (NORD), has introduced a breakthrough dental gel for long-term periodontitis treatment. The innovative low-viscosity gel features a unique active peptide and is designed for direct application into dental pockets by dentists using a syringe and flushing cannula.
The gel's key innovation lies in its formulation of triglycerides, monoglycerides, and water. Upon contact with oral cavity moisture, it forms a semi-solid bioadhesive crystalline matrix, enabling slow and localized release of the active ingredient. All components are biocompatible and FDA-approved for oral use.
Orocidin A/S, una filiale di Nordicus Partners (NORD), ha introdotto un gel dentale rivoluzionario per il trattamento a lungo termine della parodontite. Questo gel innovativo a bassa viscosità presenta un peptide attivo unico ed è progettato per essere applicato direttamente nelle tasche dentali dai dentisti utilizzando una siringa e una cannula di lavaggio.
La principale innovazione del gel risiede nella sua formulazione di trigliceridi, monogliceridi e acqua. All'atto del contatto con l'umidità della cavità orale, forma una matrice cristallina bioadesiva semi-solida, consentendo un rilascio lento e localizzato del principio attivo. Tutti i componenti sono biocompatibili e approvati dalla FDA per uso orale.
Orocidin A/S, una subsidiaria de Nordicus Partners (NORD), ha presentado un gel dental innovador para el tratamiento a largo plazo de la periodontitis. Este gel de baja viscosidad cuenta con un péptido activo único y está diseñado para ser aplicado directamente en los bolsillos dentales por dentistas utilizando una jeringa y una cánula de irrigación.
La clave de la innovación del gel radica en su formulación de triglicéridos, monoglicéridos y agua. Al entrar en contacto con la humedad de la cavidad oral, forma una matriz cristalina bioadhesiva semi-sólida, permitiendo una liberación lenta y localizada del ingrediente activo. Todos los componentes son biocompatibles y aprobados por la FDA para uso oral.
Orocidin A/S는 Nordicus Partners (NORD)의 자회사로, 장기적인 치주염 치료를 위한 혁신적인 치과 젤을 소개했습니다. 이 혁신적인 저점도 젤은 독창적인 활성 펩타이드를 특징으로 하며 치과의사가 주사기와 세척 캐뉼라를 사용하여 치아 주머니에 직접 적용할 수 있도록 설계되었습니다.
젤의 주요 혁신은 트리글리세리드, 모노글리세리드 및 물의 조성에 있습니다. 구강 내 습기와 접촉하면 반고체 생체 부착 크리스탈 매트릭스를 형성하여 활성 성분을 느리고 국소적으로 방출할 수 있게 합니다. 모든 성분은 생체 적합성이며 구강 사용을 위해 FDA 승인을 받았습니다.
Orocidin A/S, une filiale de Nordicus Partners (NORD), a introduit un gel dentaire révolutionnaire pour le traitement à long terme de la parodontite. Ce gel innovant à faible viscosité contient un peptide actif unique et est conçu pour être appliqué directement dans les poches dentaires par les dentistes à l'aide d'une seringue et d'une canule de rinçage.
L'innovation clé du gel réside dans sa formulation de triglycérides, de monoglycérides et d'eau. Au contact de l'humidité de la cavité buccale, il forme une matrice cristalline bioadhésive semi-solide, permettant un relâchement lent et localisé de l'ingrédient actif. Tous les composants sont biocompatibles et approuvés par la FDA pour un usage oral.
Orocidin A/S, eine Tochtergesellschaft von Nordicus Partners (NORD), hat ein bahnbrechendes Dentalgel zur langfristigen Behandlung von Parodontitis eingeführt. Das innovative, niedrigviskose Gel enthält ein einzigartiges aktives Peptid und wurde für die direkte Anwendung in Zahntaschen durch Zahnärzte mit einer Spritze und einer Spülkanüle entwickelt.
Die Hauptinnovation des Gels liegt in seiner Zusammensetzung aus Triglyceriden, Monoglyceriden und Wasser. Bei Kontakt mit der Feuchtigkeit der Mundhöhle bildet es eine halbsolide bioadhäsive Kristallmatrix, die eine langsame und gezielte Freisetzung des aktiven Inhaltsstoffs ermöglicht. Alle Komponenten sind biokompatibel und von der FDA für den Einsatz im Mund zugelassen.
- Development of innovative dental gel product for periodontitis treatment
- FDA-approved components for oral use
- Proprietary technology for controlled drug release
- No revenue projections or market size estimates provided
- No timeline for commercial launch mentioned
- No clinical trial data or efficacy results presented
BEVERLY HILLS, California, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has developed a novel, proprietary dental gel that represents a significant breakthrough in the long-term treatment of periodontitis.
This innovative low-viscosity gel, featuring a unique active ingredient, offers an effective and convenient solution for long-term management of this widespread oral health condition. The gel is applied by dentists using a syringe and flushing cannula to deliver the treatment directly into dental pockets. Upon contact with oral cavity moisture, the gel forms a semi-solid, bioadhesive crystalline matrix. This structure enables the slow and localized release of the active peptide, ensuring sustained treatment efficacy over time.
The formulation leverages an optimized ratio of triglycerides, monoglycerides, and water. When exposed to water naturally present in the oral cavity, the gel rapidly forms a semi-solid bioadhesive crystalline matrix, enabling the slow, localized release of the active peptide for effective, long-term treatment of periodontitis. All components are biocompatible and FDA-approved for oral use, ensuring safety and effectiveness for patients.
“Oricidin’s innovative dental gel represents a significant advancement in the treatment of periodontitis,” said Allan Wehnert, Founder and CEO of Orocidin. “By combining cutting-edge science with patient-centered design, we aim to improve both outcomes and the overall dental care experience,”.
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666 0750
Email hr@nordicuspartners.com
Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What is the new dental gel product announced by Nordicus Partners (NORD) in January 2025?
How does Orocidin's new dental gel technology work for periodontitis treatment?
Are the components in NORD's new dental gel FDA-approved?
What is the delivery method for Orocidin's new periodontitis treatment?
